Treatment of Intracranial Infection by Extensively Drug-Resistant Acinetobacter Baumannii After Craniocerebral Surgery.
Humans
Acinetobacter baumannii
/ drug effects
Acinetobacter Infections
/ drug therapy
Anti-Bacterial Agents
/ therapeutic use
Amikacin
/ therapeutic use
Tigecycline
/ therapeutic use
Drug Resistance, Multiple, Bacterial
Male
Polymyxin B
/ therapeutic use
Drug Therapy, Combination
Retrospective Studies
Minocycline
/ therapeutic use
Injections, Spinal
Middle Aged
Female
Adult
Injections, Intravenous
Journal
The Journal of craniofacial surgery
ISSN: 1536-3732
Titre abrégé: J Craniofac Surg
Pays: United States
ID NLM: 9010410
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
received:
27
06
2024
accepted:
12
07
2024
medline:
18
10
2024
pubmed:
18
10
2024
entrez:
17
10
2024
Statut:
ppublish
Résumé
The clinical outcome of intracranial infections caused by extensively drug-resistant Acinetobacter baumannii (XDRAB) remains unsatisfactory, even when treated with combined antibiotic therapy. This study successfully cured 1 patient with XDRAB intracranial infection after cranial surgery through a multichannel combination of drugs, providing a reference for the clinical treatment of severe XDRAB intracranial infection. The clinical data of a patient with an XDRAB intracranial infection after a craniocerebral operation were retrospectively analyzed, and the treatment approach for XDRAB intracranial infection was examined. Upon the occurrence of XDRAB intracranial infection after craniocerebral surgery, the patient was given an intravenous injection of polymyxin B+ tigecycline + amikacin, while intrathecal injection of polymyxin B, and the intracranial infection was controlled and cured. Polymyxin B+ tigecycline + amikacin intravenous and intrathecal polymyxin B can benefit XDRAB intracranial infected patients after craniofacial surgery.
Identifiants
pubmed: 39418529
doi: 10.1097/SCS.0000000000010542
pii: 00001665-202410000-00092
doi:
Substances chimiques
Anti-Bacterial Agents
0
Amikacin
84319SGC3C
Tigecycline
70JE2N95KR
Polymyxin B
J2VZ07J96K
Minocycline
FYY3R43WGO
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e673-e675Informations de copyright
Copyright © 2024 by Mutaz B. Habal, MD.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Malyi I. Use of a geometrical projection to determine rotational shifts in fracture fragments. Vestn Rentgenol Radiol 1988;6:82–83
Suzuki T, Morioka S, Nomoto H, et al. Disseminated Streptococcus anginosus invasive infection with intracranial subdural abscess formation. J Infect Chemother 2022;28:696–698
Yue Z, Zhi X, Bi L, et al. Treatment and prognostic risk factors for intracranial infection after craniocerebral surgery. Neurosurg Rev 2023;46:199
Touray M, Ladouceur M, Bouchardy J, et al. Arrhythmic burden of adult survivors with repaired total anomalous pulmonary venous connection. CJC Pediatr Congenit Heart Dis 2022;1:263–269
Huang Q, Zhang X, Jia A, et al. The pharmacokinetics/pharmacodynamics and neurotoxicity of tigecycline intraventricular injection for the treatment of extensively drug-resistant Acinetobacter baumannii intracranial infection. Infect Drug Resist 2022;15:4809–4817
Chen L, Li X, Li D, et al. Efficacy and safety of intraventricular polymyxin B plus continuous ventricular drainage for the treatment of intracranial infection caused by drug-resistant Acinetobacter baumannii. Ann Palliat Med 2022;11:490–497
Du N, Mao EQ, Yang ZT, et al. Intrathecal or intraventricular tigecycline therapy for central nervous system infection associated with carbapenem-resistant Klebsiella pneumoniae. Infect Drug Resist 2022;15:7219–7226
Huang G, Lai W, Wu D, et al. Two cases report of intrathecal tigecycline therapy for intracranial infection with Acinetobacter baumannii and review of literatures. Infect Drug Resist 2022;15:2211–2217
Huang Q, Zhou Q, Ju T, et al. Meropenem and amikacin for management of post-neurosurgical infections from Acinetobacter baumannii. Surg Infect (Larchmt) 2019;20:292–297
Terentjeva M, Steingolde Z, Meistere I, et al. Prevalence, genetic diversity and factors associated with distribution of listeria monocytogenes and other listeria spp. in cattle farms in Latvia. Pathogens 2021;10:851
Maxwell A, Ghate V, Aranjani J, et al. Breaking the barriers for the delivery of amikacin: challenges, strategies, and opportunities. Life Sci 2021;284:119883
Li Z, An Y, Li L, et al. Intrathecal injection of tigecycline and polymyxin b in the treatment of extensively drug-resistant intracranial acinetobacter baumannii infection: a case report and review of the literature. Infect Drug Resist 2022;15:1411–1423
Hu Y, Li D, Zhang G, et al. Intraventricular or intrathecal polymyxin B for treatment of post-neurosurgical intracranial infection caused by carbapenem-resistant gram-negative bacteria: a 8-year retrospective study. Eur J Clin Microbiol Infect Dis 2024;43:875–884
Sun X, Zhang Y, Zhang L, et al. Long course of polymyxin B for the treatment of brain abscess caused by carbapenem-resistant Acinetobacter baumannii: a case report. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2021;33:1370–1372
Wu M, Zhao J, Liu Z, et al. Intrathecal injection of polymyxin b in a child with meningitis caused by carbapenem-resistant pseudomonas aeruginosa: a case report and literature review. Infect Drug Resist 2024;17:249–258